Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Crispr Therapeutics AG (CRSP) vs Raymond James Financial, Inc. (RJF) Price & Performance

Crispr Therapeutics AGTrade
Raymond James Financial, Inc.Trade

Price performance (Past 24H)

Key statistics

Crispr Therapeutics AG vs Raymond James Financial, Inc. — how do they compare? Crispr Therapeutics AG trades at $53.98 (market cap $5.23B), while Raymond James Financial, Inc. trades at $179.97 (market cap $34.63B). The key difference: Raymond James Financial, Inc. is far larger — about 6.6× Crispr Therapeutics AG's market cap, and Raymond James Financial, Inc. pays a 1.2% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.

CRSPRJF
Market Cap
$5.23B$34.63B
Sector
HealthFinancials
52-Week High
$76.78$180.55
52-Week Low
$44.34$140.89
Enterprise Value
$3.65B
Dividend Yield
1.2%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.

Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.

Raymond James Financial, Inc.

Raymond James Financial (RJF) trades at $181.18, up 1.17% with strong technical momentum including a golden cross formation. The company reported record Q3 2026 earnings of $3.14 per share, beating estimates by 7.2%, driven by 16% revenue growth to $3.93 billion. Analyst consensus remains positive with 44% buy ratings and a $183.75 price target, slightly above current levels. The stock shows bullish moving average signals while RSI indicates potential overbought conditions near-term.

RJF demonstrates solid fundamental growth with consistent earnings beats and expanding profit margins, though valuation appears fair at current levels. Key risks include market sensitivity to capital markets performance and competitive advisor recruitment landscape. The technical setup suggests near-term resistance around $182, while fundamental strength supports longer-term upside potential if revenue momentum continues.

Returns comparison

Trailing returns across standard periods

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP

About Raymond James Financial, Inc.

Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.

Read more on RJF